|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-3-6
|
|
pubmed:abstractText |
Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT). Dosimetry and pharmacokinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) were combined and assessed for correlations with toxicity data.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Indium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Yttrium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/ibritumomab tiuxetan,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0161-5505
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
465-74
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12621016-Adult,
pubmed-meshheading:12621016-Aged,
pubmed-meshheading:12621016-Aged, 80 and over,
pubmed-meshheading:12621016-Antibodies, Monoclonal,
pubmed-meshheading:12621016-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:12621016-Antigens, CD20,
pubmed-meshheading:12621016-Bone Marrow,
pubmed-meshheading:12621016-Half-Life,
pubmed-meshheading:12621016-Humans,
pubmed-meshheading:12621016-Immunoconjugates,
pubmed-meshheading:12621016-Indium Radioisotopes,
pubmed-meshheading:12621016-Kidney,
pubmed-meshheading:12621016-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12621016-Middle Aged,
pubmed-meshheading:12621016-Radiation Dosage,
pubmed-meshheading:12621016-Radioimmunotherapy,
pubmed-meshheading:12621016-Radiotherapy Dosage,
pubmed-meshheading:12621016-Recurrence,
pubmed-meshheading:12621016-Tissue Distribution,
pubmed-meshheading:12621016-Yttrium Radioisotopes
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
|
|
pubmed:affiliation |
Nuclear Medicine, Department of Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. gwiseman@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I,
Clinical Trial, Phase III
|
